1-12 of 12
Devender Dhanda
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Real World Outcomes with Idecabtagene Vicleucel (Ide-Cel) CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma

Surbhi Sidana, Nausheen Ahmed, Othman S Akhtar, Michael Heim, Ruta Brazauskas, Doris K. Hansen, Christopher Ferreri, Ciara Louise L. Freeman, Aimaz Afrough, Larry D. Anderson, Jr., Binod Dhakal, Devender Dhanda, Lohith Gowda, Hamza Hashmi, Melanie Harrison, Amani Kitali, Sayeef Mirza, Jinalben Patel, Pallavi Patwardhan, Saad Z Usmani, Krina K. Patel, Siddhartha Ganguly, Marcelo Pasquini
Journal: Blood
Blood (2023) 142 (Supplement 1): 1027.
https://doi.org/10.1182/blood-2023-181762
Published: 2023
Journal Articles

Effects of Idecabtagene Vicleucel (Ide-Cel) Versus Standard Regimens on Health-Related Quality of Life (HRQoL) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Who Had Received 2-4 Prior Regimens: Updated Results from the Phase 3 KarMMa-3 Trial

Michel Delforge, Krina K. Patel, Laurie Eliason, Devender Dhanda, Ling Shi, Shien Guo, Thomas S. Marshall, Bertrand Arnulf, Michele Cavo, Ajay K. Nooka, Salomon Manier, Natalie S. Callander, Sergio A. Giralt, Hermann Einsele, Sikander Ailawadhi, Mihaela Popa-McKiver, Mark Cook, Paula Rodriguez Otero
Journal: Blood
Blood (2023) 142 (Supplement 1): 96.
https://doi.org/10.1182/blood-2023-179152
Published: 2023
Journal Articles

Clinical Outcomes in Real-World Patients (RW) with Triple-Class Exposed (TCE) Relapsed/Refractory Multiple Myeloma (RRMM): A Retrospective Study Using Electronic Health Records from Flatiron Health and COTA Vantage Databases

Hans C. Lee, Sundar Jagannath, Devender Dhanda, Teofilia Acheampong, Pallavi Patwardhan, Thomas S. Marshall, Suvina Amin, Tao Gu, Sikander Ailawadhi
Journal: Blood
Blood (2023) 142 (Supplement 1): 3775.
https://doi.org/10.1182/blood-2023-173661
Published: 2023
Journal Articles

Idecabtagene Vicleucel (ide-cel) Versus Standard (std) Regimens in Patients (pts) with Triple-Class-Exposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): Updated Analysis from KarMMa-3

Paula Rodríguez Otero, Sikander Ailawadhi, Bertrand Arnulf, Krina K. Patel, Michele Cavo, Ajay K. Nooka, Salomon Manier, Natalie S. Callander, Luciano Costa, Ravi Vij, Nizar J Bahlis, Philippe Moreau, Scott R. Solomon, Ingerid Weum Abrahamsen, Rachid Baz, Annemiek Broijl, Christine Chen, Sundar Jagannath, Noopur S. Raje, Christof Scheid, Michel Delforge, Reuben Benjamin, Thomas Pabst, Shinsuke Iida, Jesus G. Berdeja, Anna Truppel-Hartmann, Rashmi Bhatnagar, Fan Wu, Julia Piasecki, Laurie Eliason, Devender Dhanda, Jasper Felten, Andrea Caia, Mark Cook, Mihaela Popa-McKiver, Sergio A. Giralt
Journal: Blood
Blood (2023) 142 (Supplement 1): 1028.
https://doi.org/10.1182/blood-2023-178933
Published: 2023
Journal Articles

Effects of Idecabtagene Vicleucel (Ide-Cel) Versus Standard Regimens on Health-Related Quality of Life (HRQoL) in Patients with Triple-Class-Exposed (TCE) Relapsed/Refractory Multiple Myeloma (RRMM) Who Received at Least 3 Lines of Prior Antimyeloma Regimens in the KarMMa-3 Phase 3 Randomized Controlled Trial

Michel Delforge, Krina K. Patel, Laurie Eliason, Devender Dhanda, Ling Shi, Shien Guo, Thomas S. Marshall, Bertrand Arnulf, Michele Cavo, Ajay K. Nooka, Salomon Manier, Natalie S. Callander, Sergio A. Giralt, Hermann Einsele, Sikander Ailawadhi, Mihaela Popa-McKiver, Mark Cook, Paula Rodríguez Otero
Journal: Blood
Blood (2023) 142 (Supplement 1): 1003.
https://doi.org/10.1182/blood-2023-173849
Published: 2023
Journal Articles

Patient (pt) Experiences of Receiving Idecabtagene Vicleucel (Ide-Cel, bb2121) Versus Standard (Std) Regimens for the Treatment (Tx) of Relapsed/Refractory Multiple Myeloma (RRMM) in the Randomized, Controlled KarMMa-3 Clinical Trial: Analysis of Longitudinal Qualitative Interviews

Paula Rodríguez Otero, Krina K. Patel, Noopur S. Raje, Olga Moshkovich, Heather Gerould, Jennifer Devlen, Devender Dhanda, Laurie Eliason, Mark Cook, Mihaela Popa-McKiver, Salomon Manier
Journal: Blood
Blood (2023) 142 (Supplement 1): 2385.
https://doi.org/10.1182/blood-2023-173840
Published: 2023
Journal Articles

Health-Related Quality of Life (HRQoL) in Patients with Relapsed and Refractory Multiple Myeloma (RRMM) Who Are Triple-Class Exposed to an Immunomodulatory Agent, a Proteasome Inhibitor, and an Anti-CD38 Antibody

Nina Shah, Ravi Vij, Jenna S. Roberts, Ivana Rajkovic, Rebecca Silbermann, Jens Hillengass, Sujith Dhanasiri, Julia Braverman, Abigail McMillan, Devender Dhanda
Journal: Blood
Blood (2022) 140 (Supplement 1): 13259–13261.
https://doi.org/10.1182/blood-2022-158235
Published: 2022
Journal Articles

Updated Health-Related Quality of Life Results from the KarMMa Clinical Study in Patients with Relapsed and Refractory Multiple Myeloma Treated with the B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy Idecabtagene Vicleucel (ide-cel, bb2121)

Michel Delforge, Nina Shah, Paula Rodríguez-Otero, Julia Braverman, Devender Dhanda, Ling Shi, Shien Guo, Peiwen Yu, Weiqin Liao, Timothy B. Campbell, Nikhil C. Munshi
Journal: Blood
Blood (2021) 138 (Supplement 1): 2835.
https://doi.org/10.1182/blood-2021-145155
Published: 2021
Journal Articles

Matching-Adjusted Indirect Comparisons of Efficacy Outcomes in Patients with Relapsed and Refractory Multiple Myeloma for Idecabtagene Vicleucel (KarMMa) Versus Selinexor Plus Dexamethasone (STORM Part 2) and Belantamab Mafodontin (DREAMM-2): Updated Analysis with Longer Follow-up

Paula Rodríguez-Otero, Ali Mojebi, Dieter Ayers, Devender Dhanda, James Farrell, Faith E. Davies, Michel Delforge, Katja Weisel, Kevin Towle, Tom Marshall, Clyde Caisip, Shannon Cope
Journal: Blood
Blood (2021) 138 (Supplement 1): 1978.
https://doi.org/10.1182/blood-2021-145321
Published: 2021
Journal Articles

Idecabtagene Vicleucel (ide-cel, bb2121), a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy: Qualitative Analyses of Post-Treatment Interviews (Months 6-24) for Patients with Relapsed and Refractory Multiple Myeloma in the Karmma Clinical Trial

Nina Shah, Michel Delforge, Paula Rodríguez-Otero, Olga Moshkovich, Julia Braverman, Devender Dhanda, Sally Lanar, Jennifer Devlen, Matthew Miera, Heather Gerould, Timothy B. Campbell, Nikhil C. Munshi
Journal: Blood
Blood (2021) 138 (Supplement 1): 3041.
https://doi.org/10.1182/blood-2021-145166
Published: 2021
Journal Articles

Secondary Quality-of-Life Domains in Patients with Relapsed and Refractory Multiple Myeloma Treated with the Bcma-Directed CAR T Cell Therapy Idecabtagene Vicleucel (ide-cel; bb2121): Results from the Karmma Clinical Trial

Nina Shah, MD, Michel Delforge, Jesús F. San-Miguel, Kaitlyn B. Bertin, Muna J Tahir, Hannah B. Lewis, Julie Wang, PharmD, PhD, Julia Braverman, PhD, Timothy B. Campbell, MD PhD, Devender Dhanda, Nikhil C. Munshi, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 28–29.
https://doi.org/10.1182/blood-2020-136665
Published: 2020
Journal Articles

A Matching-Adjusted Indirect Comparison of Efficacy Outcomes for Idecabtagene Vicleucel (ide-cel, bb2121), a Bcma-Directed CAR T Cell Therapy Versus Conventional Care in Triple-Class-Exposed Relapsed and Refractory Multiple Myeloma

Nina Shah, MD, Dieter Ayers, Faith E. Davies, Shannon Cope, Ali Mojebi, Kejal Parikh, Devender Dhanda, Parameswaran Hari, MD MRCP, Payal Patel, Liping Huang, PhD, Kristen Hege, Sujith Dhanasiri
Journal: Blood
Blood (2020) 136 (Supplement 1): 6–7.
https://doi.org/10.1182/blood-2020-136730
Published: 2020